Aclarion's Nociscan: AI-Powered Solution for Chronic Low Back Pain Diagnosis Proves Cost-Effective

Aclarion Introduces Innovative AI-Powered Diagnostic Tool for Chronic Low Back Pain

Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company, has developed Nociscan, an innovative diagnostic tool leveraging artificial intelligence to address the global issue of chronic low back pain (cLBP). With approximately 266 million people worldwide suffering from degenerative spine disease and low back pain, Nociscan aims to revolutionize the diagnosis and treatment of this pervasive condition 1

1

2

Nociscan: AI-Driven Precision in Pain Localization

Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms to quantify chemical biomarkers associated with disc pain 1

1

3

Cost-Effectiveness Analysis Demonstrates Nociscan's Superiority

A peer-reviewed article published in Clinicoeconomics and Outcomes Research has revealed the cost-effectiveness of Nociscan compared to traditional provocative discography. The analysis concludes that Nociscan is not only effective but also less costly, saving $1,712 per patient and improving surgical success rates by 10% 2

2

Dr. Doug Beall, Chief of Radiology Services at Clinical Radiology of Oklahoma and co-author of the study, emphasized the importance of this research: "Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography" 2

2

Implications for Healthcare Providers and Payers

Ryan Bond, Chief Strategy Officer at Aclarion, highlighted the significance of these findings for both healthcare providers and payers: "We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community" 2

2

3

Related Stories

Aclarion's CLARITY Trial for Nociscan: A Breakthrough in Chronic Low Back Pain Diagnosis

Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies

Transcarent and Accolade Merger Advances: HSR Waiting Period Expires for AI-Powered Healthcare Combination

Transcarent to Acquire Accolade: A Merger Powered by AI in Healthcare

Aclarion's Market Position and Future Prospects

Aclarion is positioning itself as a leader in the chronic low back pain diagnostic market. The company recently presented at the Planet MicroCap Showcase: VEGAS 2025, where CEO Brent Ness discussed recent value-driving initiatives 1

1

In conjunction with this event, Aclarion has published an updated investor presentation, available on their website, showcasing the company's progress and future plans 1

1

Technological Infrastructure and Process

Nociscan operates through a cloud connection, receiving MRS data from MRI machines for each lumbar disc being evaluated. Proprietary signal processing techniques in the cloud extract and quantify chemical biomarkers associated with disc pain. This data is then processed through proprietary algorithms to indicate potential pain sources 1

1

2

3

As Aclarion continues to develop and refine its AI-powered diagnostic tools, the company is poised to make significant strides in addressing the complex issue of chronic low back pain, potentially transforming patient care and treatment strategies in the field of spinal health.